Terumo Interventional Systems Unveils Innovative Imaging Solutions
Terumo Interventional Systems, a prominent division of Terumo Corporation, has made significant strides in the realm of cardiac care through the recent launch of their groundbreaking OPUSWAVE® Dual Sensor Imaging System. This innovative system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), marking a pivotal moment for the company and healthcare providers focused on treating coronary artery disease.
Advanced Imaging Capabilities
The OPUSWAVE Imaging System incorporates sophisticated technologies, merging Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) within a single catheter. This merger allows physicians to obtain simultaneous views, which can greatly enhance their ability to evaluate and manage coronary artery disease (CAD). This cutting-edge approach positions Terumo as a leader in imaging technology, especially as it expands its presence in the U.S. market.
Key Features of the OPUSWAVE Imaging System
The DualView imaging catheter, central to the OPUSWAVE Imaging System, is engineered with remarkable features that significantly benefit interventional cardiologists. With a maximum pullback length of 150mm and an impressive 2.6 Fr. imaging profile, it ensures compatibility with 6 Fr. guides. Furthermore, the variable pullback speed of up to 40mm/second in dual mode optimizes procedural efficiency.
Enhancing Efficiency and Outcomes
According to Ghada Farah, President of Terumo Interventional Systems, the OPUSWAVE Imaging System revolutionizes imaging efficiency without compromising on quality. It enables healthcare professionals to develop comprehensive treatment plans, ultimately striving for the best possible patient outcomes. The marriage of both OFDI and IVUS functionalities within a single catheter offers substantial advantages, reducing procedure time and associated costs.
Targeted Solutions for Interventional Cardiology
Dr. Michael J. Martinelli, Chief Medical Officer at Terumo Medical Corporation, emphasizes that this innovative imaging technology serves as a game changer for interventional cardiologists engaged in image-guided percutaneous coronary interventions (PCI). The ability to leverage both imaging modalities with ease allows physicians to address a broader range of lesions, providing flexibility and enhancing decision-making capabilities during procedures.
About Terumo Interventional Systems
Terumo Interventional Systems, as a specialized division of Terumo Corporation, stands at the forefront of minimally invasive treatment technologies. The organization is widely recognized for its commitment to advancing techniques related to entry site management, lesion access, and therapeutic interventions. Their product portfolio is integral to various advanced treatments, particularly in the arenas of coronary, peripheral, and endovascular procedures.
About Terumo Corporation
Founded in Tokyo in 1921, Terumo (TSE: 4543) has established itself as a global leader in medical innovation. The company is driven by a deep-seated commitment to societal improvement through healthcare, which resonates across over 160 countries and regions. Terumo consistently endeavors to deliver a wide array of solutions that facilitate better therapeutic outcomes and operational efficiency in hospitals.
Frequently Asked Questions
What is the OPUSWAVE Imaging System?
The OPUSWAVE Imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) in a single catheter to improve coronary artery disease evaluations.
How does the DualView imaging catheter benefit physicians?
The DualView catheter allows for a 150mm maximum pullback length and supports varying speeds up to 40mm/second, enhancing procedural efficiency.
What makes Terumo Interventional Systems innovative?
They blend advanced imaging technologies in their products and maintain a robust focus on improving patient outcomes in interventional cardiology.
When was the OPUSWAVE Imaging System cleared by the FDA?
It received its 510(k) clearance from the FDA, enhancing Terumo's product offerings in the U.S. market.
What is Terumo's mission and history?
Terumo is dedicated to contributing to society through healthcare, founded in 1921 and operating in over 160 countries to provide quality medical solutions.
